In metastatic breast cancer, the status of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), as well as the Ki-67 index sometimes change between primary and metastatic lesions. However, the change in expression levels of enhancer of zeste homolog 2 (EZH2) between primary and metastatic lesions has not been determined in metastatic breast cancer. Ninety-six metastatic breast cancer patients had biopsies or resections of metastatic lesions between September 1990 and February 2014 at the Kanagawa Cancer Center. We evaluated ER, PR, HER2, Ki-67, and EZH2 in primary lesions and their corresponding metastatic lesions using immunohistochemistry. We examined the change in expression of EZH2 between primary and metastatic lesions, the correlation between the expression of EZH2 and the expression of other biomarkers, and the relationship between EZH2 expression and patient outcome in metastatic breast cancer. EZH2 expression was significantly higher in metastatic lesions compared with primary lesions. EZH2 expression was highly correlated with Ki-67 expression in primary and metastatic lesions. High-level expression of EZH2 was associated with poorer disease-free survival (DFS) outcomes in patients with primary lesions (P < 0.001); however, high-level expression of EZH2 was not associated with poorer DFS outcomes in patients with metastatic lesions (P = 0.063). High-level expression of EZH2 was associated with poorer overall survival (OS) postoperatively in patients with primary (P = 0.001) or metastatic lesions (P = 0.005). High-level expression of EZH2 was associated with poorer OS outcomes after recurrence in patients with metastatic lesions (P = 0.014); however, high-level expression of EZH2 was not associated with poorer OS outcomes after recurrence in patients with primary lesions (P = 0.096). High-level expression of EZH2 in metastatic lesions was independently associated with poorer OS outcomes after recurrence. EZH2 expression was significantly increased in metastatic lesions compared with primary lesions. High-level expression of EZH2 in metastatic lesions was associated with poorer OS outcomes after primary surgery and recurrence.
E23227 Background: Enhancer of zeste homolog 2 (EZH2), a Polycomb group protein, has been linked to aggressive breast cancer. Few reports have examined EZH2 expression in metastatic lesions of breast cancer patients. Therefore, the purpose of this study was to investigate the clinicopathological significance of EZH2 expression in metastatic breast cancers (MBCs). Methods: We retrospectively studied the surgical specimens of primary breast cancer (PBC) tumors and their corresponding metastatic lesions from patients (n= 96) who underwent surgery for the PBC tumor between December 1977 and March 2013. Tissue microarrays (TMAs) and whole tissue sections were constructed, using primary and metastatic lesions, and stained with antibodies against estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki-67, and EZH2. We examined the correlations between ER, PR, HER2, Ki-67, and EZH2 expression, and the clinicopathological characteristics and outcome measures of the patients. Results: Compared to primary lesions, metastatic lesions exhibited significantly higher levels of expression of Ki-67 (75.0% vs. 42.7%, P= 0.01) and EZH2 (71.9% vs. 56.3%, P< 0.0001). Ki-67 expression was significantly highly correlated with EZH2 expression in primary lesions and metastatic lesions. Patients expressing high levels of EZH2 in primary lesions were not associated with poorer overall survival (OS) outcomes after recurrence than patients expressing low levels of EZH2 in primary lesions (P = 0.096), whether patients expressing high levels of EZH2 in metastatic lesions were associated with significantly than patients expressing low levels of EZH2 (P = 0.014). High levels of EZH2 expression in metastatic lesions were independently associated with poorer OS outcomes after recurrence. Conclusions: We show that high EZH2 expression levels in metastatic lesions are independently more associated with poorer OS outcomes after recurrence than primary lesions.